Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00984191
Other study ID # NapadonChula_01
Secondary ID
Status Active, not recruiting
Phase N/A
First received September 24, 2009
Last updated June 23, 2011
Start date March 2010
Est. completion date November 2011

Study information

Verified date June 2011
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority Thailand: Ethical Committee
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to see if the 99mTechnetium-MIBI SPECT-CT can be a tool for preoperative evaluation of cervical node metastasis in papillary thyroid cancer.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date November 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- papillary thyroid cancer

Exclusion Criteria:

- pregnancy

- Bleeding abnormality

- Prior history of head and neck cancer

- can not perform 99mTechnetium-MIBI SPECT-CT

- can not perform 131I remnant Ablation

- Prior any head and neck surgery within 3 months

- Prior deep neck infection within 3 months

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Intervention

Radiation:
99mTc-MIBI SPECT-CT
99mTc-MIBI SPECT-CT for abnormal cervical lymph node

Locations

Country Name City State
Thailand King Chulalongkorn Hospital Pathumwan Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic Tool Statistic (PPV , NPV , Sensitivity , Specificity , Accuracy ) 18 months No
See also
  Status Clinical Trial Phase
Completed NCT01441154 - Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
Active, not recruiting NCT04544111 - PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Phase 2
Recruiting NCT03469011 - A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer. Phase 1
Recruiting NCT05752669 - Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
Recruiting NCT04076514 - The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
Active, not recruiting NCT01723202 - Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Phase 2
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Active, not recruiting NCT02568267 - Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Phase 2
Unknown status NCT02140476 - Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy N/A
Recruiting NCT06286631 - Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
Completed NCT06325787 - Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma N/A
Terminated NCT01974284 - Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma N/A
Active, not recruiting NCT04731467 - A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05668962 - Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Phase 2
Completed NCT02178345 - Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
Not yet recruiting NCT06133374 - Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
Completed NCT03470259 - Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging Phase 1
Active, not recruiting NCT04129411 - Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation N/A
Recruiting NCT03899792 - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Phase 1/Phase 2
Completed NCT05873283 - Papillary Thyroid Cancer and Central Lymp Node Dissection